In this study, we confirmed that SQP could ameliorate NASH in rats by improving hepatic inflammation and simultaneously screened four hub inflammation-related target genes (PTGS2, JUN, MYC, and CDKN1A) via network pharmacology and bioinformatics analysis. This evidence concerns the gene CDKN1A and metabolic dysfunction-associated steatohepatitis.